NasdaqGS:KURABiotechs
How Caspian Launch Has Changed The Investment Story At Kura Oncology Stock (KURA)
Kura Oncology has contributed next generation menin inhibitor assets, including KO-7246, to newly launched Caspian Therapeutics and received equity, a reimbursement of up to US$1.5 million, and an intercompany services arrangement, while Caspian secured US$50 million in external funding to advance diabetes and cardiometabolic programs.
The structure leaves Kura Oncology with roughly half ownership, board representation, and ongoing research service fees. This ties long term economic upside...